• SolarBank and Viridi are collaborating on a 3.06 MW solar and 1.2 MWh battery energy storage system in Buffalo, New York, repurposing a closed landfill, converting unused land into a source of clean energy.
• Pending approvals and financing, SolarBank is set to begin construction, while Viridi will provide the battery storage system.
• Viridi’s battery systems include integrated fire suppression and anti-propagation technology to enhance safety.
• Once operational, the project will function under a community solar model, where residents can subscribe to the project, earning credits on their electricity bills without installing personal solar panels.

Disseminated on behalf of SolarBank Corporation

SolarBank (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2), a premier developer and owner of renewable and clean energy projects, specializing in distributed and community solar initiatives throughout Canada and the U.S., has announced a partnership with Viridi, the industry leader in fail-safe battery energy storage systems (“BESS”), to develop a combined 3.06 megawatt (“MW”) direct current ground-mounted solar power project and a 1.2 megawatt-hour (“MWh”) BESS, in Buffalo, New York. This initiative aims to transform a closed landfill into a productive asset that generates clean energy for the local community (https://ibn.fm/XEmgk).

The selected site, located at 1037 South Park Ave. in South Buffalo, was previously a landfill. By repurposing this land, the project not only addresses environmental concerns but also contributes to the community by providing a sustainable energy source. This approach exemplifies innovative land use, turning otherwise unusable areas into hubs for renewable energy production.

Once operational, the project will function under a community solar model. This setup allows local residents, including renters and homeowners, to subscribe to the solar project. Subscribers receive credits on their electricity bills corresponding to their share of the generated solar energy, enabling them to benefit from renewable energy without the need to install personal solar panels. This model promotes inclusivity and broad participation in clean energy initiatives.

Viridi, known for its leadership in fail-safe battery energy storage systems, will supply the BESS for this project. Their innovative lithium-ion battery packs are equipped with integrated fire suppression and pioneering anti-propagation technology. Unlike traditional methods that modify battery cells, Viridi’s design isolates each cell to prevent thermal runaway, ensuring that a single cell failure does not escalate. This fail-safe approach enhances safety and reliability, making the energy storage solution adaptable for various settings.

SolarBank, subject to the receipt of financing, intends to be the owner of the project. The company has secured a lease for the project site and has applied for interconnection approval. Upon receiving the necessary permits and financing, the company plans to commence construction. The integration of the BESS with the solar installation will allow for the storage of generated energy, which can be dispatched during peak demand periods, thereby enhancing grid stability and optimizing energy use. This project aligns with New York State’s energy storage roadmap, which supports the development of such hybrid generation-storage projects.

SolarBank has already begun construction on another BESS project, representing the company’s first foray into this sector. The company has kicked off construction of project SFF-06, one out of two battery energy storage systems in Ontario, earlier in February 2025, through a $25.8 million CAD ($18.17 million USD) project finance facility from the Royal Bank of Canada. The initiatives come as battery storage demand surges, with the global market projected to reach $31.2 billion USD by 2029, growing at 16.3% annually (https://ibn.fm/G6g5b).

For more information, visit the company’s website at SolarBankCorp.com. This report contains forward looking information. Please refer to https://ibn.fm/G76GJ for additional details.

NOTE TO INVESTORS: The latest news and updates relating to SUUN are available in the company’s newsroom at https://ibn.fm/SUUN

• Brera Holdings, an Ireland-based, international holding company with a global portfolio of men’s and women’s sports clubs, remains on track to acquire a 52% stake in Italian Serie B soccer club SS Juve Stabia
• Its investments are paying off, with Andrea Adorante, a star forward on the team, now having an estimated purchase value of close to €6-7 million, projected to climb to €8-10 million should he continue at his current goal-scoring pace
• Adorante has scored 12 goals with 2 assists so far in the current football season and could end up with 18 at that pace, winning fans and media, plus Player of the Week on the 26^th week of the season
• Adorante’s valuation could surpass Brera’s €7.5 million investment for its SS Juve Stabia acquisition, as well as the Nasdaq company’s current estimated overall valuation, all pointing to a massive overlooked opportunity for any investor

Brera Holdings (NASDAQ: BREA), an Ireland-based, international holding company focused on expanding its global portfolio of men’s and women’s sports clubs through a multi-club ownership (“MCO”) approach, remains on track to acquire a 52% stake in Italian Serie B club, SS Juve Stabia “The Second Team of Naples.” Andrea Adorante, a star forward at the team, already has an estimated purchase value of between €6 to €7 million, projected to climb to €8-10 million should he continue at his current pace, according to Italian media reports. 

Brera Holdings, with a portfolio comprising six teams globally covering primarily both men’s and women’s football clubs, currently holds a 38.46% ownership equity in Juve Stabia, with the third and last of the multi-step acquisition set to close on March 31, 2025, making Brera the majority shareholder in the club (https://ibn.fm/XchS6).

Amazingly, this means that a single player for the Brera club Juve Stabia has an estimated asset sales value as high as that of the current full purchase price Brera is paying for its majority ownership of The Second Team of Naples, making it a significant overlooked opportunity for investors.

Earlier in February, it was estimated in an independent CFA research report that Juve Stabia’s 2025 revenue would increase by $5.15 million, with Brera’s overall revenue forecast estimated at between $6.3 million and $9.8 million. The projections have implied a market capitalization of $55.76 million by 2027, further projecting its MCO model’s viability (https://ibn.fm/W7S1D).

“Brera Holdings has made a strategic move with the Juve Stabia acquisition, and while challenges remain, the company is positioning itself for significant revenue growth,” noted Sascha P. Czerwenka, CFA, for 247MarketNews.com. “If operational improvements continue as expected, the stock could see a major re-rating, presenting a compelling opportunity for investors,” he added (https://ibn.fm/W7S1D).

So far in the current football season, Adorante has scored 12 goals and is projected to end up with 18 for the season. This impressive feat marks a striking year since he joined Juve Stabia on January 4, 2024. The 25-year-old Italian has made 25 match appearances for Juve Stabia, getting two assists in addition to his 12 goals (https://ibn.fm/OSsHd). He has also won accolades, including Player of the Week on the 26^th week of the current season, and has become a media and fan star. 

Having a single player with a higher estimated purchase value than that of the overall club, let alone the Nasdaq-listed company Brera that owns it, makes no sense, and should represent a hidden buying opportunity to any investor.

For company information, visit the company’s website at www.BreraHoldings.com.

NOTE TO INVESTORS: The latest news and updates relating to BREA are available in the company’s newsroom at https://ibn.fm/BREA

• One of the most significant challenges facing biotechnology companies is securing adequate funding to sustain research and development efforts.
• Calidi’s improved financial footing reassures investors and allows the company to focus on achieving key milestones in its research pipeline.
• The company has been selected to present new data on its RTNova systemic virotherapy platform at the prestigious AACR annual meeting in April 2025.

Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotechnology company, is making significant strides in the field of cancer immunotherapy. Known for its innovative approach to antitumor virotherapies, Calidi is focused on harnessing the power of its patented technology that protects and potentiates the virotherapy during administration (extracellular enveloped viruses in its systemic platform and stem cells in its intratumoral platforms) to target and destroy cancer cells while simultaneously stimulating the immune system. The company’s groundbreaking work has positioned it as a leader in the development of next-generation cancer treatments.

In recent news, Calidi has made two major announcements that underscore its progress, one related to its strengthened financial position and another highlighting its acceptance into a prestigious scientific seminar to present new research. These developments signal the company’s growth and its continued advancement toward commercializing its therapies.

One of the most significant challenges facing biotechnology companies is securing adequate funding to sustain research and development efforts. Calidi Biotherapeutics recently announced that it has strengthened its financial position, ensuring continued progress in its clinical and preclinical programs (https://ibn.fm/9JicX). As of Dec. 31, 2024, Calidi reported a cash balance of approximately $9.6 million. This increase is largely due to successful fundraising efforts, including proceeds from the company’s At-the-Market Offering Agreement (“ATM”).

As a result of these efforts, Calidi was able to terminate its Standby Equity Purchase Agreement (“SEPA”) with YA II PN Ltd., an affiliate of Yorkville Advisors, effective Jan. 23, 2025. The infusion of capital will allow the company to further refine its oncolytic virotherapy platforms, expand its clinical trials, and enhance its overall operational stability.

Additionally, Calidi announced the successful closing of a public offering on Jan. 10, 2025, which raised an additional $4.25 million in gross proceeds. This contributes to the ongoing development of Calidi’s proprietary technologies and supports the company’s mission to bring effective cancer therapies to market. This improved financial footing not only reassures investors but also allows Calidi to focus on achieving key milestones in its research pipeline. With adequate funding in place, the company is well-positioned to continue its groundbreaking work in cancer immunotherapy.

Beyond its financial achievements, Calidi Biotherapeutics has also made headlines for its acceptance into a major scientific conference where it will present its latest research findings (https://ibn.fm/WZ1RO). The company announced that it has been selected to present new data on its RTNova systemic virotherapy platform at the prestigious American Association for Cancer Research (“AACR”) annual meeting in April 2025.

This recognition marks an important milestone for Calidi, as the AACR annual meeting is one of the most influential conferences in the field of cancer research. Being accepted to present at this event underscores the significance of Calidi’s work and its potential to revolutionize cancer treatment.

Calidi’s RTNova platform is designed to overcome the limitations of traditional virotherapy by enabling systemic delivery and enhancing the targeting of metastatic tumors. Antitumor virotherapies have long been recognized for their ability to selectively infect and kill cancer cells, but challenges such as immune system clearance and limited distribution have hindered their full potential. The RTNova platform addresses these challenges by utilizing an extracellular enveloped virus (“EEV”) as a delivery mechanism, allowing the therapeutic viruses to reach tumors more effectively while evading premature destruction by the immune system. These preclinical findings highlight the RTNova platform’s ability to effectively target and treat metastatic cancer cells and represent a significant advancement in the field of cancer virotherapy.

In addition to the RTNova platform, Calidi is actively developing other innovative therapies aimed at harnessing the immune system to combat cancer. The company’s approach to immunotherapy focuses on protecting the viral payload to enhance the efficacy of antitumor viruses, potentially improving outcomes for patients with hard-to-treat cancers.

With a strengthened financial position and the recognition of its research by a leading scientific organization, Calidi Biotherapeutics is poised for continued growth. The company’s ability to secure funding ensures that it can maintain momentum in its clinical and preclinical programs, while its acceptance into a high-profile scientific seminar validates the importance of its work. As Calidi moves forward, it is well-positioned to make a lasting impact in the biotechnology industry. With continued innovation and a strong financial foundation, the company is set to play a crucial role in the future of cancer immunotherapy.

For more information, visit www.CalidiBio.com.

NOTE TO INVESTORS: The latest news and updates relating to CLDI are available in the company’s newsroom at https://ibn.fm/CLDI

• Adageis streamlines complex insurance contracts, helping providers maximize reimbursements.
• The company’s AI-driven solutions reduce administrative burden, freeing up time for patient care.
• Seamless integration with nearly 100 EHR systems ensures a smooth transition to value-based care models.
• The company’s fintech approach enhances financial performance, with providers seeing up to $75,000 in additional revenue.
• Adageis projects significant growth, expecting to cover 580,000 patient lives by mid-2025.

Healthcare is shifting toward value-based care, where providers are reimbursed for patient outcomes rather than the number of procedures performed. While the model promises higher-quality care at lower costs, it also introduces complex reimbursement structures that can be difficult to navigate.

Adageis, a healthcare technology company providing smart AI-centric software solutions for healthcare organizations, is helping providers optimize care delivery while maximizing revenue. The company’s AI-driven platform integrates with nearly 100 electronic health record (“EHR”) systems, making it easy for medical practices to track performance metrics and meet insurers’ evolving documentation requirements.

“One of the major challenges in the marketplace is the sheer complexity — there are over 100 insurance companies with more than 1,000 plans in the Phoenix area alone. Each has different measures and unique documentation requirements… Adageis has a solution that integrates with nearly 100 electronic health record systems, overlaying existing platforms to provide easy-to-read measures tailored to each patient’s insurance,” Adageis CEO Shane Speirs said during a recent podcast (https://ibn.fm/7yFnW).

According to Speirs, what Adageis focuses on is to provide a simple solution to healthcare organizations — ranging from large, multi-state, multi-specialty healthcare groups to independent practices across the country. “We offer a solution that meets everyone’s needs, helping providers and organizations drive revenue by delivering high-quality care, which everyone can align with,” the Adageis CEO said. “Much of the value in value-based care comes from providing proper documentation to patients and being proactive with screenings. We provide an easy solution for practices to indicate the metrics needed for patients, to provide high-quality care while maximizing incentive dollars.”

Another issue the healthcare system is facing is the fact that administrative tasks, such as clinical documentation and coding, consume valuable time that could be spent on patient care. Adageis addresses this issue with its AI Scribe technology, which uses ambient listening to automate documentation and coding. By leveraging AI, the platform:

• Reduces administrative workload, allowing providers to focus on patient care.
• Generates high-quality coding, ensuring maximum reimbursement.
• Minimizes errors in documentation, lowering the risk of rejected claims.

This approach enhances financial performance, with some providers seeing up to $75,000 in additional annual revenue from value-based care incentives, according to figures listed in the company’s investor deck.

Adageis is positioning itself as a leader in healthcare fintech, as the only healthcare fintech company in the marketplace, bridging the gap between financial optimization and improved patient care. The company’s growth projections underscore its increasing market presence:

• Currently covering 150,000 patient lives, with plans to reach 580,000 by mid-2025.
• $100,000 in monthly recurring revenue expected by Q2 2025.
• Expanding provider base, onboarding 2-3 new clients per month.

By integrating financial technology with AI-driven healthcare solutions, Adageis is reshaping how providers approach value-based care, ensuring better patient outcomes while driving revenue growth. Allowing providers to simplify complex financial structures while maintaining quality care, Adageis offers a scalable, easy-to-implement platform, reducing inefficiencies and ensuring forward-thinking providers thrive in a rapidly evolving landscape.

For more information, visit the company’s website at www.Adageis.com.

NOTE TO INVESTORS: The latest news and updates relating to Adageis are available in the company’s newsroom at https://ibn.fm/Adageis

Traders, dealers, businesses, and enthusiasts of the cannabis industry are invited to attend the New England Cannabis Convention in Boston from March 21 to March 22, 2025. Operating since 2015, NECANN events are referred to as “MJBizCon East.” The second largest B2B event in the U.S., NECANN witnesses thousands of attendees, with the largest gathering of licensed operators, exhibitors, buyers, and leaders, for the East Coast cannabis market. These events are considered the home base for the Northeast cannabis industry.

The Boston NECANN Convention 2025 will also host the prize-giving ceremony for the Boston NECANN Cup winners on March 22, 2025. Registrations for this close on February 23, 2025. Applications are also invited to judge the NECANN Boston Cup. The NECANN Cup is New England’s only multi-state cannabis competition, a third-party blind evaluation of cannabis and cannabis products (https://ibn.fm/duCNZ).

NECANN events are considered a major benefit to the Northeast cannabis industry, offering a phenomenal platform for networking and business to the local cultivators, traders, pharmacies, and more. Each year, the event witnesses 9,000+ attendees, interacting, networking, and attending the 60+ programming sessions. Over 300+ exhibitors, with 100+ licensed cultivators, retailers, and brands, exhibit their latest products and technologies on the exhibition floor.

Investors can discover new avenues of investment while entrepreneurs can gain visibility among the leading businesses and experts in the cannabis industry. Cannabis industry stalwarts will conduct the different programming sessions at NECANN Boston. They will address the most compelling cannabis industry topics faced by operators in Massachusetts. Some important topics that will be covered include regulatory compliance services, consumer market study, and advocacy of psychedelic-assisted therapies in conservative states, to name a few.

To learn more, please visit https://ibn.fm/KSQ7t.

• According to the American Cancer Society, cancer is the second leading cause of death globally.
• Oncology drugs are a cornerstone of modern cancer treatment.
• Calidi Biotherapeutics is a cutting-edge biotechnology company dedicated to developing innovative cancer treatments.

Cancer continues to be one of the most significant health challenges of our time, with its global impact growing every year. The increasing number of cancer diagnoses and related deaths underscores the urgent need for more effective treatments, including advanced oncology drugs. Companies such as Calidi Biotherapeutics (NYSE American: CLDI) are at the forefront of research and development, offering hope for millions of patients worldwide.

According to the American Cancer Society, cancer is the second leading cause of death globally, with 2,001,140 new cancer cases and 611,720 cancer deaths projected to occur in the United States in 2024 (https://ibn.fm/JA0DN). Approximately one in six deaths worldwide is due to cancer. The global cancer burden is expected to rise to 28.4 million cases by 2040, a 47% increase from 2020. This surge is driven by population growth, aging, and lifestyle factors such as tobacco use, poor diet, and physical inactivity.

Among the most prevalent and deadly forms of cancer are lung cancer, which is responsible for 1.8 million deaths annually, making it the leading cause of cancer-related mortality (https://ibn.fm/woQzB); colorectal cancer, which accounts for nearly 935,000 deaths each year (https://ibn.fm/ms7ty); breast cancer, the most commonly diagnosed cancer, with more than 2.3 million new cases annually (https://ibn.fm/O313h); and stomach and liver cancers, which account for approximately 968,784 (https://ibn.fm/zyWfM) and 866,136 deaths per year, respectively (https://ibn.fm/4EvTp).

These statistics highlight the enormous need for effective cancer treatments, especially for high-mortality cancers such as glioblastoma (“GBM”), triple-negative breast cancer (“TNBC”), sarcoma and certain types of lung cancer.

Oncology drugs are a cornerstone of modern cancer treatment. These drugs range from traditional chemotherapy to targeted therapies and immunotherapies, which aim to enhance the body’s immune response against cancer cells. Oncology drugs play a vital role in:

• Extending Survival: Many advanced therapies have significantly improved survival rates for cancers once considered untreatable.
• Improving Quality of Life: Targeted treatments and immunotherapies often come with fewer side effects than traditional chemotherapy, allowing patients to maintain a better quality of life.
• Personalized Medicine: Advances in genetic testing have enabled the development of personalized oncology drugs tailored to the unique genetic makeup of a patient’s tumor.

The global oncology drug market was valued at approximately $158 billion in 2022 and is projected to reach $327 billion by 2037, reflecting a compound annual growth rate (“CAGR”) of 7.5% (https://ibn.fm/xBVyH). However, despite these advances, significant gaps remain in treatment efficacy, accessibility, and affordability, underscoring the urgent need for continued innovation.

Calidi Biotherapeutics is a cutting-edge biotechnology company dedicated to developing innovative cancer treatments. Their unique approach leverages antitumor virotherapies and patented technologies designed to protect and potentiate the virotherapy during administration to combat cancer more effectively and with fewer side effects. Calidi’s therapeutic strategy centers on harnessing the power of antitumor virotherapies, which are engineered to selectively infect and destroy cancer cells while sparing healthy tissue.

To enhance the delivery and efficacy of these viruses, Calidi uses extracellular enveloped viruses in its systemic platform and stem cells in its intratumoral platforms to protect the virotherapy from the body’s immune system during administration. The company’s dual approach offers multiple advantages, including targeted tumor destruction, in which viruses directly attack cancer cells, leading to their destruction; and immune system activation, a process that triggers a systemic immune response and trains the immune system to recognize and attack cancer cells throughout the body.

Calidi’s robust pipeline includes three key product candidates:

• RTNova (“CLD-400”): Targeting lung cancer and metastatic cancer, RTNova is a systemic platform that can be administered intravenously. The technology includes a vaccinia virus enveloped with a human cell membrane designed to protect the viral payload from the body’s immune system during administration and home in on cancer cells.
• SuperNova (“CLD-201”): Targeting solid tumors such as head and neck, triple-negative breast cancer and soft tissue sarcoma, SuperNova combines mesenchymal stem cells with vaccinia viruses. This therapy aims to overcome the limitations of traditional treatments by directly targeting tumors and activating the immune system.
• NeuroNova (“CLD-101”): This therapy is designed for patients with glioblastoma and other high-grade gliomas. It utilizes neural stem cells to deliver antitumor viruses directly to brain tumors, offering a promising new approach for one of the most aggressive and treatment-resistant cancers.

Calidi is also developing next-generation engineered antitumor viruses to broaden the scope of cancers treatable with its platform.

The groundbreaking work being done by Calidi Biotherapeutics has the potential to transform the oncology drug market and significantly improve cancer care. By focusing on high-need cancer types such as GBM, TNBC, sarcoma and lung cancer, Calidi addresses critical gaps in current treatment options. The company’s innovative therapies not only aim to improve survival rates but also reduce the debilitating side effects associated with many existing cancer treatments. As Calidi’s products advance through clinical trials, they hold the promise of offering new hope to patients facing some of the most challenging cancers.

The global burden of cancer continues to grow, making the need for effective oncology drugs more pressing than ever. As a leader in innovative cancer treatment, Calidi Biotherapeutics is poised to play a pivotal role in shaping the future of oncology drug development. Its pioneering therapies represent a new frontier in the fight against cancer, offering hope for improved outcomes and a better quality of life for millions of patients worldwide.

For more information, visit www.CalidiBio.com.

NOTE TO INVESTORS: The latest news and updates relating to CLDI are available in the company’s newsroom at https://ibn.fm/CLDI

• The company’s six-month revenue reached $20.1 million CAD ($14.15 million USD), reflecting steady long-term growth despite seasonal fluctuations.
• Gross profit margin increased to 29.2%, up from 18.4% in the prior year, signaling improved margins.
• Assets surged 372% to $185.3 million CAD ($130.47 million USD) during the six month period, following the acquisition of Solar Flow-Through Funds Ltd.
• Recent $70.3 million CAD ($49.5 million USD) deal with Qcells will drive revenue in upcoming quarters.
• Share price more than doubled in early February, signaling investor interest.

Disseminated on behalf of SolarBank Corporation

SolarBank (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2), a premier developer and owner of renewable and clean energy projects, specializing in distributed and community solar initiatives throughout Canada and the U.S., posted its fiscal 2025 second-quarter results, emphasizing its six-month revenue of $20.1 million CAD ($14.15 million USD) and improved gross margins. According to the Q2 results, the company’s gross profit rose to $5.9 million CAD ($4.15 million USD) (or 29.2% of revenues), from $4.8 million CAD ($3.38 million USD) in 2024, reflecting a shift toward higher-margin business lines (https://ibn.fm/F30Jw).

Additionally, independent power producer (“IPP”) revenue increased from CAD $0.14 million ($0.07 million USD) to $5.4 million CAD ($3.8 million USD) during the same six-month period, with assets growing 372% to $185.3 million CAD ($130.47 million USD) following the acquisition of Solar Flow-Through Funds Ltd., as compared to $39.2 million CAD ($27.6 million USD) on June 30, 2024. The company ended the second quarter of fiscal 2025 with $33.6 million CAD ($23.66 million USD) in current assets, as compared to $17.6 million CAD ($12.39 million USD) in current assets as of year-end June 30, 2024. The increase is principally the result of the closing of the Solar Flow-Through Funds acquisition.

In addition to the encouraging Q2 results, the company’s stock saw a sharp rally in early February, rising from $3.86 CAD ($2.72 USD) on Jan. 31 to $9.08 CAD ($6.39 USD) by Feb. 10. While the price has since stabilized, the spike suggests growing investor interest in the company’s strategic direction and upcoming projects (https://ibn.fm/ZiPvC).

Beyond the current financials report, SolarBank is positioning itself for sustained expansion moving forward, recently securing additional major financing and strategic partnerships:

• $70.3 million CAD ($49.5 million USD) transaction with Qcells to sell and construct four solar projects in New York, with revenues to be recognized in future quarters (https://ibn.fm/QOyJY). The projects will utilize high-quality Qcells modules that will be manufactured in the U.S. The deal is part of the nearly $2.8 billion USD being invested by Qcells to boost U.S. domestic solar manufacturing and innovation to support and accelerate the U.S. clean energy transition.
• $25.8 million CAD ($18.17 million USD) project finance facility from RBC to develop two battery energy storage systems (“BESS”) in Ontario, a sector with strong long-term growth potential. Representing the company’s first foray into the battery storage sector, construction on the first project, SFF-06, began during the Feb. 10 week (https://ibn.fm/5WEhQ).
• 145 MW of solar projects in the pipeline, expected to reach notice to proceed within the next 12 months.

These projects reinforce SolarBank’s focus on securing stable, recurring revenue streams, including independent power production.

CEO Richard Lu acknowledged that seasonal factors affected Q2 revenue, a common trend in the solar industry, especially in winter months. However, higher-margin power production and asset growth offset the slight decline, leading to improved overall gross profits. “This is stable recurring revenue that is under long-term contracts, and we will continue to grow this business as evidenced by the $25.8 million Royal Bank of Canada debt facility that supports the construction of the BESS projects that we own,” Lu said.

The CEO also pointed out that delays in EPC (engineering, procurement, and construction) revenue were expected, as the company focused on securing a strong development partner. The Qcells deal, finalized at the end of the quarter, means these revenues will now be reflected in the coming periods, he added.

SolarBank’s strong asset growth, rising profit margins, and new revenue streams from power production and storage projects position the company well for continued success. With a robust project pipeline and investor interest reflected in the recent stock price rally, SolarBank sees itself well-positioned for sustained growth in the renewable energy market.

For more information, visit the company’s website at SolarBankCorp.com. This report contains forward looking information. Please refer to https://finance.yahoo.com/news/solarbank-announces-second-quarter-results-120000457.html and the press release referenced in this article for additional details on the nature, assumptions and risk factors associated with this forward looking information.

NOTE TO INVESTORS: The latest news and updates relating to SUUN are available in the company’s newsroom at https://ibn.fm/SUUN

• Manufacturing within the U.S. offers numerous benefits that can significantly impact a company’s operational efficiency and market competitiveness
• The Massimo Group’s recent announcement highlights the company’s proactive approach in leveraging these benefits
• “We are committed to providing our customers with the highest quality golf carts while ensuring long-term business sustainability,” states the CEO

In recent years, manufacturing goods in the United States has become increasingly advantageous for companies aiming to enhance quality control, reduce lead times and navigate complex international trade dynamics. Recent tariff announcements have made the move to U.S. soil even more compelling. Massimo Group (NASDAQ: MAMO), a prominent player in the powersports industry, has exemplified this trend by announcing the relocation of its MVR Golf Cart series production to its Garland, Texas, facility (https://ibn.fm/34Aav). This strategic move not only underscores the benefits of domestic manufacturing but also aligns with the company’s vision of delivering superior products while adapting to evolving market conditions.

Manufacturing within the U.S. offers numerous benefits that can significantly impact a company’s operational efficiency and market competitiveness. One of the primary advantages is enhanced quality control. By situating production facilities domestically, companies can closely monitor manufacturing processes, ensuring that products meet stringent quality standards. This proximity facilitates immediate oversight and swift response to any issues that may arise during production, thereby maintaining high-quality outputs.

Another notable benefit is the reduction in lead times. Domestic manufacturing eliminates the lengthy shipping durations associated with overseas production. This reduction not only accelerates the time-to-market for products but also enables companies to respond more rapidly to market demands and consumer needs. Shorter lead times can lead to increased customer satisfaction and a more agile supply chain.

Furthermore, manufacturing in the U.S. can result in decreased costs, including tariff and delivery charges. Producing goods closer to the consumer reduces transportation expenses, which can be a significant portion of a product’s overall cost. Lower delivery costs can enhance a company’s profitability and offer competitive pricing advantages in the marketplace.

Massimo Group’s recent announcement highlights the company’s proactive approach in leveraging these benefits. In response to U.S. trade regulators imposing countervailing duties and antidumping tariffs on certain foreign manufacturers accused of unfair trade practices, Massimo has decided to shift the production of its MVR Golf Cart series to its existing facility in Garland, Texas. This decision is aimed at enhancing quality control and strengthening the company’s presence in the U.S. market.

“We are committed to providing our customers with the highest quality golf carts while ensuring long-term business sustainability,” said David Shan, CEO of Massimo Motor. “Bringing production to our Texas facility strengthens our supply chain, enhances quality assurance and positions us competitively in the U.S. market. Our customers and dealer partners can continue to rely on Massimo for innovative and reliable personal transportation solutions.”

By relocating production domestically, Massimo is poised to mitigate the financial impact of international tariffs and duties. This move not only safeguards the company from potential cost increases associated with imported goods but also aligns with a broader trend of reshoring manufacturing operations to the United States. Reshoring can provide companies with greater control over their supply chains and reduce exposure to global trade uncertainties.

The Massimo Group has established itself as a significant entity in the powersports sector. The company’s product portfolio includes a range of off-road vehicles, such as all-terrain vehicles (“ATVs”), utility task vehicles (“UTVs”), and golf carts. By focusing on innovation and quality, Massimo has cultivated a reputation for delivering reliable and high-performance vehicles tailored to diverse consumer needs.

The company’s vision centers on providing exceptional products that enhance the recreational and professional experiences of its customers. By prioritizing quality and customer satisfaction, Massimo aims to be a leader in the powersports industry, continually adapting to market trends and consumer preferences.

For more information, visit the company’s website at massimomotor.com, massimomarine.com and massimoelectric.com

NOTE TO INVESTORS: The latest news and updates relating to MAMO are available in the company’s newsroom at https://ibn.fm/MAMO

• As cancer numbers grow, Calidi Biotherapeutics is at the forefront of developing novel treatments aimed at improving patient outcomes.
• Calidi’s platform centers on the use of antitumor virotherapies that selectively infect and kill cancer cells while activating the body’s own immune system to attack the tumor.
• The company’s therapeutic pipeline targets multiple cancer indications, with a focus on hard-to-treat tumors.

Cancer remains a significant global health challenge, with certain types exhibiting particularly high mortality rates. Glioblastoma multiforme (“GBM”), triple-negative breast cancer (“TNBC”), sarcoma and lung cancer are among the most aggressive and deadly forms, necessitating urgent advancements in research and treatment. Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage immuno-oncology company pioneering proprietary technology designed to attack solid tumors, empowering the immune system to combat cancer.

According to studies, GBM is the most common and aggressive primary brain tumor in adults (https://ibn.fm/55xHJ). Despite treatment, the median survival time is approximately 12 to 15 months, with a five-year survival rate of less than 7%. TNBC accounts for about 10–15% of all breast cancers (https://ibn.fm/gR3FS) and is characterized by its lack of estrogen, progesterone, and HER2 receptors, making it unresponsive to some of the most effective therapies. It tends to grow and spread faster than other breast cancers, with fewer treatment options and a poorer prognosis.

Lung cancer is the second most common cancer in both men and women in the United States (https://ibn.fm/xSbgu). In 2024, an estimated 234,580 new cases will be diagnosed, and approximately 125,070 people will die from the disease. The five-year survival rate remains low, emphasizing the need for improved therapeutic strategies.

In the face of these challenges, Calidi Biotherapeutics is at the forefront of developing novel treatments aimed at improving outcomes for patients with these and other cancers. Their approach leverages cutting-edge science to enhance the body’s natural defenses against cancer.

Calidi’s platform centers on the use of antitumor virotherapies that selectively infect and kill cancer cells. To enhance the delivery and efficacy of these viruses, Calidi employs patented technologies (extracellular enveloped viruses in its systemic platform and stem cells in its intratumoral platforms) designed to protect the virotherapy from the immune system until it reaches the tumor site. This method not only facilitates direct tumor destruction but also stimulates an immune response against cancer cells throughout the body.

Calidi’s therapeutic pipeline targets multiple cancer indications, with a focus on hard-to-treat tumors. Its pipeline includes RTNova, SuperNova and NeuroNova.

RTNova is a systemic platform that can be administered intravenously to target lung cancer and metastatic cancers. The technology includes a vaccinia virus enveloped with a human cell membrane designed to protect the viral payload from the body’s immune system during administration and home in on cancer cells.

Aimed at treating solid tumors, SuperNova combines mesenchymal stem cells with antitumor vaccinia virus to target and destroy cancer cells. This approach holds potential for addressing cancers such as head & neck, TNBC and soft tissue sarcoma, where conventional treatments have limited efficacy.

NeuroNova is a product designed for patients with newly diagnosed and recurrent high-grade gliomas, including GBM. NeuroNova utilizes neural stem cells engineered to deliver antitumor viruses directly to the tumor site. The therapy is advancing into Phase 1b/2 clinical trials, reflecting promising results.

Calidi Biotherapeutics’ innovative therapies have the potential to revolutionize cancer treatment by enhancing efficacy, stimulating immune response and addressing unmet needs. For cancers such as GBM, head & neck, TNBC, sarcoma and lung cancer, where current treatments are often inadequate, Calidi’s approach offers promising new potential.

The pressing need for effective treatments for these aggressive cancers underscores the importance of innovative research and development in oncology. Calidi Biotherapeutics’ pioneering work in harnessing the power of antitumor viruses and its patented technologies designed to protect the viral payload from the body’s immune system during administration represents significant advancements in the fight against these deadly diseases. As Calidi’s therapies progress through clinical trials, there is hope for improved outcomes and survival rates for patients facing these challenging cancers.

For more information, visit www.CalidiBio.com.

NOTE TO INVESTORS: The latest news and updates relating to CLDI are available in the company’s newsroom at https://ibn.fm/CLDI

• D-Wave’s Qubits 2025 quantum computing user conference will be held in Scottsdale, Arizona, March 31 and April 1, as well as a virtual livestream of the first day’s talks.
• The event will feature presentations from D-Wave executives, customers and industry thought leaders, highlighting product and technical roadmap updates, scientific advancements, the intersection of quantum and AI, and more.
• Presentations will showcase how the company’s quantum technology is delivering tangible value today.

D-Wave Quantum Inc. (NYSE: QBTS) (“D-Wave”), a leader in quantum computing systems, software and services, and the first supplier of production-grade quantum computers, announced that its Qubits 2025 quantum computing user conference will be held in Scottsdale, Arizona, on March 31 and April 1. This year’s event, themed “Quantum Realized,” will feature presentations from D-Wave executives, customers and industry thought leaders, showcasing how the company’s quantum technology solutions are delivering tangible value today. It also serves as an important component of the company’s recently launched integrated brand campaign of the same name (https://ibn.fm/HXHqu).

Speakers will share groundbreaking work based on their use of D-Wave quantum technology to solve problems today, including D-Wave customers Davidson Technologies, Jülich Supercomputing Centre (Forschungszentrum Jülich), Japan Tobacco, Momentum Worldwide, NTT DOCOMO, Pusan National University, Quantum Research Sciences, SAS, the University of Southern California’s Viterbi School of Engineering, and more.

Qubits 2025 will feature:

• D-Wave’s latest quantum innovations, product roadmap and vision for advancing quantum technology,
• The latest groundbreaking quantum research underway from labs and universities around the world using D-Wave^TM technology,
• Recent developments at the intersection of quantum and AI,
• Talks and live demonstrations showcasing real-world quantum applications across logistics and manufacturing, government, life sciences, financial services, and more, and
• Breakout sessions with D-Wave technical advisors to help participants fast track their quantum journey.

Those unable to attend the event in person will be able to register for and access a free livestream of the first day’s talks on the Qubits website (https://ibn.fm/xs2jS).

A premier event for the global quantum community and organizations interested in realizing value from today’s quantum computers, Qubits 2025 comes at a time when quantum computing is quickly moving from experimentation to applications in production, amid a growing need for businesses, governments and scientific organizations to understand how to leverage the technology to address challenges that are beyond the reach of classical computers.

The event’s theme and D-Wave brand campaign, “Quantum Realized,” aims to demonstrate that quantum computing is not just a theoretical future breakthrough—it is delivering value right now via D-Wave technology that is solving complex problems for industries including logistics, retail, manufacturing, and more. According to D-Wave CEO Dr. Alan Baratz, quantum is here, now, and D-Wave’s quantum technology is helping businesses, researchers and governments address their most computationally complex problems today.

“Qubits 2025 is an incredible opportunity to engage with the trailblazing innovators at the center of this quantum transformation,” Dr. Baratz said. “It’s a must-attend event for anyone looking to harness the remarkable power of this technology to strengthen business operations, achieve new scientific breakthroughs, and capitalize on the beneficial relationship between quantum and AI.”

About D-Wave Quantum Inc.

D-Wave is a leader in the development and delivery of quantum computing systems, software, and services. We are the world’s first commercial supplier of quantum computers, and the only company building both annealing and gate-model quantum computers. Our mission is to help customers realize the value of quantum, today. Our 5,000+ qubit Advantage^TM quantum computers, the world’s largest, are available on-premises or via the cloud, supported by 99.9% availability and uptime. More than 100 organizations trust D-Wave with their toughest computational challenges. With over 200 million problems submitted to our Advantage and Advantage2^TM systems to date, our customers apply our technology to address use cases spanning optimization, artificial intelligence, research and more. Learn more about realizing the value of quantum computing today and how we’re shaping the quantum-driven industrial and societal advancements of tomorrow: www.dwavequantum.com.

NOTE TO INVESTORS: The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS